Mesenchymal stem cells receive adaptive islet-derived miR-151-containing sEVs to promote β cell compensation in obesity
Quick Facts
- Publication title: Mesenchymal stem cells receive adaptive islet-derived miR-151-containing sEVs to promote β cell compensation in obesity
- Journal: Sci Adv
- Year: 2026
- DOI: 10.1126/sciadv.adu4196
- PMID/PMCID: 42467765; PMC13378542
Research overview
This study shows that adaptive islet-derived small extracellular vesicles (aid-sEVs) play a key role in β cell adaptation in obesity. These findings reveal a critical pathway controlling β cell compensation in diet-induced obesity and indicate that targeted enhancement of aid-sEV secretion could be a therapeutic strategy to counteract β cell dysfunction in diabetic patients.
Key findings
Pancreatic islets respond to obesity-related insulin resistance by increasing β cell mass and insulin secretion.
However, the molecular mechanisms behind this vital compensation are not fully understood.
This study shows that adaptive islet-derived small extracellular vesicles (aid-sEVs) play a key role in β cell adaptation in obesity.
Aid-sEV production rises under hyperlipidemic conditions, and uptake by adjacent cells occurs via F11R-mediated recognition.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification, exosome-depleted media supply; the study also used or cited Exosupur®, ExoCCM®.
Related platforms: Exoomics®, Research Reagents & Tools
Related services and capabilities: Biofluid EV Isolation & Purification, Tissue EV Isolation & Purification, Exosome-Depleted Serum / Medium Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit, ExoCCM® Exosome-Depleted Serum/Medium
References
Original publication: Mesenchymal stem cells receive adaptive islet-derived miR-151-containing sEVs to promote β cell compensation in obesity Science advances. 2026. DOI: 10.1126/sciadv.adu4196. PMID/PMCID: 42467765; PMC13378542.